Antidepressant treatment patterns and success rates in a managed care organization

Disease Management and Health Outcomes

Volumn 11, Issue 3, 2003, Pages 173-180

  Armstrong, Edward P ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; DESIPRAMINE; DOXEPIN; FLUOXETINE; IMIPRAMINE; MAPROTILINE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PROTRIPTYLINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ARTICLE; DATA BASE; DEPRESSION; HEALTH CARE COST; HUMAN; MANAGED CARE; MONOTHERAPY; TREATMENT OUTCOME;

EID: 0037288796     PISSN: 11738790     EISSN: None     Source Type: Journal    
DOI: 10.2165/00115677-200311030-00004     Document Type: Article

References (32)

1. Rupp A, Narrow W, Regier D, et al. Epidemiology and costs of depression: a hidden burden. Dis Manage Health Outcomes 1997; 2: 134-40
2. Snow V, Lascher S, Mottur-Pilson C. Pharmacologic treatment of acute major depression and dysthymia. Ann Intern Med 2000; 132: 738-42
3. Hirschfeld RMA, Keller MB, Panico S, et al. The national depressive and manic-depressive association consensus statement on the undertreatment of depression. JAMA 1997; 277: 333-40
4. Davidson JRT, Meltzer-Brody SE. The underrecognition and undertreatment of depression: what is the breadth and depth of the problem? J Clin Psychiatry 1999; 60 Suppl. 7: 4-9
5. Campbell LK, Robison LM, Skaer TL, et al. Depression: interventions and their effectiveness. Dis Manage Health Outcomes 1997; 2: 223-37
6. Hirschfeld RMA, Keller MB, Panico S, et al. The national depressive and manic-depressive association consensus statement on the undertreatment of depression. JAMA 1997; 277: 333-40
7. Olfson M, Marcus SC, Druss B, et al. National trends in the outpatient treatment of depression. JAMA 2002; 287: 203-9
8. Skaer TL, Sclar DA, Robison LM, et al. Trend in the use of antidepressant pharmacotherapy and diagnosis of depression in the US: an assessment of office-based visits 1990 to 1998. CNS Drugs 2000; 14: 473-81
9. Venturini F, Sung JCY, Nichol MB, et al. Utilization patterns of antidepressant medications in a patient population served by a primary care medical group. J Managed Care Pharm 1999; 5: 243-9
10. Melfi CA, Chawla AJ, Croghan TW, et al. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry 1998; 55: 1128-32
11. Edgell ET, Summers KH, Hylan TR, et al. A framework for drug utilization evaluation in depression: insights from outcomes research. Med Care 1999; 37: AS67-76
12. Thompson D, Buesching D, Gregor KJ, et al. Patterns of antidepressant use and their relation to costs of care. Am J Manag Care 1996; 2: 1239-46
13. Russell JM, Berndt ER, Miceli R, et al. Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline. Am J Manag Care 1999; 5: 597-606
14. McCombs JS, Nichol MB, Stimmel GL. The role of SSRI antidepressants for treating depressed patients in the California Medicaid (Medi-Cal) program. Value Health 1999; 2: 269-80
15. Melfi CA, Croghan TW. Use of claims data for research on treatment and outcomes of depression care. Med Care 1999; 37: AS77-80
16. Agency for Health Care Policy and Research. Depression in primary care: volume 2. Treatment of major depression (no. 5). Washington, DC: Public Health Service, US Department of Health and Human Services. 1993. AHCPR Publication no. 93-0551
17. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992; 45: 197-203
18. Streja DA, Hui RL, Streja E, et al. Selective contracting and patient outcomes: a case study of formulary restrictions for selective serotonin reuptake inhibitor antidepressants. Am J Manag Care 1999; 5: 1133-42
19. Kroenke K, West SL, Swindle R, et al. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. JAMA 2001; 286: 2947-55
20. Rascati K, Godley P, Pham H. Evaluation of resources used to treat adverse events of selective serotonin reuptake inhibitor use. J Manag Care Pharm 2001; 7: 402-6
21. Simon GE, Von Korff M, Heiligenstein JH, et al. Initial antidepressant choice in primary care: effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA 1996; 275: 1897-902
22. Baker AM, Russell JM, Campbell JK. Variance in treatment compliance and costs by antidepressant class: analysis in an HMO setting. Formulary 2001; 36: 204-10
23. Williams JW, Mulrow CD, Chiquette E, et al. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med 2000; 132: 743-56
24. Croghan TW, Obenchain RL, Crown WE. What does the treatment of depression really cost? Health Aff (Millwood) 1998; 17: 198-208
25. Hylan TR, Crown WH, Meneades L, et al. Tricyclic antidepressant and selective serotonin reuptake inhibitors antidepressant selection and health care costs in the naturalistic setting: a multivariate analysis. J Affect Disord 1998; 47: 71-9
26. Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization. J Int Med Res 1995; 23: 395-412
27. Thompson D, Hylan TR, McMullen W, et al. Predictors of a medical-offset effect among patients receiving antidepressant therapy. Am J Psychiatry 1998; 155: 824-7
28. Lave JR, Frank RG, Schulberg HC, et al. Cost-effectiveness of treatments for major depression in primary care practice. Arch Gen Psychiatry 1998; 55: 645-51
29. Rost K, Smith GR, Matthews DB, et al. The deliberate misdiagnosis of major depression in primary care. Arch Fam Med 1994; 3: 333-7
30. Jencks SF. Recognition of mental disorder in primary care. JAMA 1985; 253: 1903-7
31. Lloyd SS, Rissing JP. Physician coding errors in patient records. JAMA 1985; 254: 1330-6
32. Conner TM, Crismon ML, Still DJ. A critical review of selected pharmacoeconomic analyses of antidepressant therapy. Ann Pharmacother 1999; 33: 364-72